Investorideas.com newswire, breaking news for marijuana, cannabis and hemp stocks

Friday, 29 October 2021

Cannabis Stock News: Ayurcann Holdings Corp. (CSE: AYUR) Completes Phase 2 Build-Out and Distributes Earn-Out Payment

Cannabis Stock News: Ayurcann Holdings Corp. (CSE: AYUR) Completes Phase 2 Build-Out and Distributes Earn-Out Payment

Investor Ideas #Potcasts 609, #Cannabis News and #Stocks on the Move; (OTCQB: $PHOT), (CSE: $BCBC.C), (NASDAQ: $ACB), (CSE: $CURA.C) (OTCQX: $CURLF)

 



Investor Ideas #Potcasts 609, #Cannabis News and #Stocks on the Move; (OTCQB: $PHOT), (CSE: $BCBC.C), (NASDAQ: $ACB), (CSE: $CURA.C) (OTCQX: $CURLF)

 

Delta, Kelowna, BC, October 29, 2021 (Investorideas.com Newswire) www.Investoride, as.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/102921-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/10291PHOT-BCBC-ACB-CURA-CURLF.asp

 

Hear Investor ideas cannabis potcast on iTunes  

 

Hear the investor ideas potcast on Spotify

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

In today’s podcast we look at a few public company announcements.

 

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading international provider of consumer products in cannabis, announced earlier this week that its initial batches of New York whole flower have cleared testing by third party labs and that sales of three initial strains began this week with the Company's Newburgh location followed by Curaleaf's Carle Place, Forest Hills, and Plattsburgh dispensaries.

 

"Our patients have been waiting a long time for this day and we couldn't be happier to be able to deliver whole flower product to all four of our New York locations in the next day or so and to the majority of our wholesale partners within the month," said Joe Bayern, CEO of Curaleaf. "Fortunately, we have been preparing for this moment and we are more than ready with plenty of product for all our New York locations. We are grateful to Governor Hochul and the OCM for moving this forward so quickly, and we look forward to robust sales and happy customers. We appreciate the patience and loyalty of all our patients as we worked toward this milestone."

 

Prior to this month, cannabis was only available to New York patients in ground form, a source of frustration for many patients who prefer the plant's medicinal applications in its purest and most natural format.

 

Curaleaf whole flower will also be available to the majority of the Company's wholesale partners in the state by the end of the month, ensuring that the Company maintains its position as the New York market leader and its product will be available throughout the state.

 

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), earlier this week, announced a manufacturing agreement with The Valens Company Inc., a leading manufacturer of cannabis products, to manufacture a new seasonal offering in the mint category.

 

Launching under Drift Turbo, the Company's mainstream adult-use recreational brand, the new Canna Cane Mints are a two-piece hard peppermint candy containing 10mg THC (5mg THC per piece). This is the first product offering under the manufacturing arrangement, which is expected to expand in the coming months.

 

"We know that Canadian cannabis consumers are looking for novelty and variety, and seasonal offerings are a key approach to strategically expanding our portfolio of adult-use products," said Miguel Martin, CEO, Aurora Cannabis. "Valens' exceptional manufacturing capabilities complement our product line up this upcoming holiday season. Our strategic relationship is designed to unlock efficiencies as we seek to bring innovation to market with speed and differentiation that connects with consumers."

 

The cannabis edibles will be manufactured using SōRSE™ by Valens emulsion technology, a patented, in-house emulsion technology that transforms cannabis oils into water-soluble forms to infuse foods, liquids and topicals without the taste or smell of cannabis.

 

Tyler Robson, Chief Executive Officer, Co-Founder and Chair of The Valens Company, said, "This is an important milestone for the Canadian cannabis market as two of the largest companies in this sector come together. We have admired Aurora for their leadership and continuing to elevate and challenge industry standards. Our companies share the same ethos when it comes to bringing the highest quality products to market and offering a premium experience to consumers."

 

Aurora's upcoming holiday portfolio will also include a new 510 vape cartridge launching under the Company's adult-use recreational brand, Daily Special. The new Cranberry Sauce 1g 510 Vape is a high-THC distillate vape and is infused with the classic sweet-tart flavour of festive cranberries. Both the Canna Cane Mints and Cranberry Sauce Vape are limited-time products and will be available for purchase in British Columbia and Alberta beginning in November. The Cranberry Sauce 1g 510 Vape will also be available for purchase in the Maritimes.

 

The BC Bud Corporation (CSE: BCBC), a house of high-quality cannabis brands based out of British Columbia, Canada, announced a partnership between its in-house craft concentrate brand, Solventless Solutions, and micro-cultivator Habitat's certified organic flower brand, Cake and Caviar.

 

An industry leading partnership, a first of its kind in Canada, Solventless Solutions will work in tandem with Habitat's Cake and Caviar to produce farm-to-table premium solventless extracts using meticulously selected cultivars to be flash frozen immediately after harvest. Through this innovative collaboration, Solventless Solutions will be the industry's premium destination for small-scale, chemical-free extraction with the ability to process biomass from micro-cultivators.

 

Engaging in the partnership with Habitat as a superior top shelf flower producer creates a seamless conduit for Solventless Solutions to begin bringing craft concentrates to the market. The Company will release concentrates under its house of brands, allowing for the building and strengthening of new infrastructure and continued relationships with cultivators. This will also allow the continual research and dynamic development for Habitat's growing genetic lineup.

 

"Working with the team at Solventless Solutions, we are excited to add top shelf rosin products to our portfolio utilizing our unique genetics. Partnering with experts is crucial in order for Habitat to continue with its existing micro operations around cultivation, research and development thus we are grateful for the opportunity to expand alongside this talented team" commented Rudi Schiebel, CEO of Habitat.

 

"The partnership between Solventless Solutions and Habitat is the first of its kind in the country, and marks a key pivot point in our mission to expand The BC Bud Co within the evolving cannabis industry," said The BC Bud Co CEO Brayden Sutton. "This exciting collaboration is key to our brand focused strategy as we continue to focus on maximizing shareholder value through relationships and partnerships."

 

GrowLife, Inc. (OTCQB: PHOT), one of the nation’s most recognized indoor cultivation product and service providers, announced that it has entered into an exclusive distribution agreement with the leading mushroom cultivation equipment supplier in Canada, My Fungi Inc., whereas the Company will have the exclusive right to market and distribute its proprietary line of mushroom cultivation equipment throughout the United States. This marks the Company’s entrance into the expanding mushroom industry, servicing both B2B and B2C customers, by supplying hard-to-find essential equipment for mushroom cultivation.

 

Mushroom cultivation has seen a significant spike in growth in recent years, with consumer demand for specialty mushrooms for food, wellness, nutraceutical, and medical purposes exploding. Mushroom cultivation is extremely specialized and requires specialized equipment to produce at large-scale. As a leader in cultivation equipment for the cannabis industry, GrowLife’s progression into offering these products through its robust network of hydroponic and ecommerce sellers is natural and aligns with the core competencies of the Company. By offering items such as liquid culture, blended and sterile substrates, and all in one kits, GrowLife is now positioned to address the demand for these products throughout the US, through a consistent supply chain created through the agreement with My Fungi.

 

“Moving into the mushroom cultivation equipment space is a natural progression for GrowLife and working with My Fungi is the perfect illustration of how we are leveraging our long history of cultivation expertise to bring innovative and high-demand products to emerging markets,” said Marco Hegyi, CEO of GrowLife. “The founder of My Fungi, Mr. Dave Auger, is a previous leader of our Canadian operations, and a long-time friend of GrowLife. Dave has built a strong supply chain for difficult to obtain equipment such as sterilized substrates which are required for cultivating food and medicinal grade mushrooms. Having one of the strongest and only supply chains of these products is a major differentiator for GrowLife and creates a completely new opportunity for growth for our Company.”

 

“I am excited to be working with GrowLife again,” stated Dave Auger, Founder of My Fungi . “Teaming up will allow My Fungi to expand into the rapidly developing mushroom cultivation markets of the United States. Sterilization is a significant pain point of mushroom cultivators, working with GrowLife will ensure that anyone interested in cultivating mushrooms will have access to the products and support needed to get growing.”

 

Beyond the emerging science around the medicinal benefits of mushrooms, mushrooms for use in food and wellness products represents a global market size of $46.1 billion in 2020, with the US being the second largest mushroom consumption market. While consumer demand for quality mushrooms rises, the supply of necessary growing equipment is becoming more constrained, fueled further by logistical issues impacting imports at US Ports. The products that GrowLife will sell through this distribution agreement are produced in North America, alleviating port issues, and stabilizing the supply chain to meet this demand.

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

 

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

 

The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) ,  Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio ,  Google Podcasts and most audio platforms available.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news,  third party stock research , guest posts and original  articles and podcasts in leading stock sectors.  Learn about investing in stocks and get  investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast ,  Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and  the AI Eye Podcast.     

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 


  Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

Friday, 22 October 2021

Investor Ideas #Potcasts 608, #Cannabis News and #Stocks on the Move; Interview with President and CEO of RIV Capital (CSE: $RIV.C) (OTC: $CNPOF)

Investor Ideas #Potcasts 608, #Cannabis News and #Stocks on the Move; Interview with President and CEO of RIV Capital (CSE: $RIV.C) (OTC: $CNPOF)

 


Delta, Kelowna, BC, October 22, 2021 (Investorideas.com Newswire) www.Investoride, as.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/102221-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/10221RIV-CNPOF.asp

 

Hear Investor ideas cannabis potcast on iTunes  

 

Hear the investor ideas potcast on Spotify

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

In today’s podcast Investorideas interviews Narbe Alexandrian, President and CEO of RIV Capital Inc. (CSE: RIV) (OTC: CNPOF), where we discussed the companyès transition from Canopy Rivers Inc. to RIV Capital, the companyès recent news and investments as well as the investment opportunities being noticed right now in the US cannabis space.

 

Discussing how Canopy Rivers transitioned into RIV Capital, Narbe Alexandrian commented, “RIV Captial started as Canopy Rivers back in 2017, and at the time we were the venture capital arm of Canopy Growth. By late 2017 we spun off to become our own entity but we were still controlled by Canopy Growth through multiple voting shares. I joined the company the summer of 2018 and we took the company public in the fall of 2018. BY January of 2019 I was promoted to President and then CEO by May of 2019. Fast forwarding to that May of 2019, where in my new role, everything I was seeing was pointing towards the US market. The market is huge, it’s underserved, there is still a lot of stigma attached to what you can do there.So I was trying everything I could to get more US exposure before anybody was really talking about US exposure. However at the time we weren’t able to go there because of Canopy Grwoth’s ties to the US legalization issues in the US. Over the next 18 months we worked to really clean up shop by unwinding deals and structures that were made while working on a deal to get us to the US market.”

 

Alexandrian continued, “In December 2020, and we closed this in February of 2021, we sold the interest in three of our portfolio companies for, at closing it was 380 million CAD, part of that was cash and part of that was Canopy Growth shares. We used a portion of that to buy out Canopy GFrowth’s position and another part of that to pay off a liability that I inherited from my predecessors. So with a chunk of cash and no control over us, we could finally get to the US market. AS we were looking at different acquisitions and investments, Scotts Miracle Gro reached out to us and that lead to the strategic investment they made on their end.”

 

The Hawthorne Collective, Inc., a cannabis-focused subsidiary of The Scotts Miracle-Gro Company (NYSE: SMG) purchased an unsecured convertible note from RIV Capital for US$150 million back in August of 2021.

 

“The closing of the investment from The Hawthorne Collective comes at a key moment for RIV Capital,” said Narbé Alexandrian, President and CEO, RIV Capital. “The ongoing uncertainty around the status of U.S. federal cannabis legalization continues to sideline significant amounts of capital, creating attractive acquisition opportunities in strategic markets. We believe we are well-positioned to capitalize on these opportunities, given our strong balance sheet and acquisition currency, and develop our operating and brand platform.”

 

Alexandrian went on to discuss where he is seeing the largest opportunities in the US, mentioning the advantages of limited license States as well as R & D potential.

 

When asked about the continued risk in the US, Alexandrian commented, “I think the biggest risk is regulatory risk. As an example, right now New York has 10 vertically integrated licenses that have been given out. These licenses give anybody the ability to cultivate, extract, process and manufacture as well as create their own dispensaries to sell their product. Each one of these licenses is worth a lof money. But what happens when the government comes in and says, hey we did 10 and now we are going to make it into 100, what happens to the value of these original 10 licenses?  So whenever we look at these businesses, even though they are in a state with limited licenses where you're going to reap the benefits for maybe 3 or 4 years, we stress test these companies and say, what does it look like if things change and you look more like California than New York and can you survive and can you pivot?”

 

Narbe Alexandrian went on to discuss some of the other potential areas of investment within the US space, how things have changed over the last two years, how things are expected to continue to develop, realistic expectations for federal cannabis reform within the US as well as potential risks and benefits of a far off globalized cannabis industry.

 

To find out more information about RIV Capital, click the link here.

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

 

To hear more Investorideas.com

 podcasts visit: https://www.investorideas.com/Audio/.

 

The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) ,  Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio ,  Google Podcasts and most audio platforms available.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news,  third party stock research , guest posts and original  articles and podcasts in leading stock sectors.  Learn about investing in stocks and get  investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast ,  Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and  the AI Eye Podcast.     

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 


  Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

 

New #Stocks to Watch -Biotech (NasdaqGS: $ERAS) (Nasdaq: $TCRX) (Nasdaq: $HCWB), Mining (CSE: $GMR.C) (CSE: $ATHA.C) Cannabis (CSE: $XBRA.C)

  New #Stocks to Watch -Biotech (NasdaqGS: $ERAS) (Nasdaq: $TCRX) (Nasdaq: $HCWB), Mining (CSE: $GMR.C) (CSE: $ATHA.C) Cannabis (CSE: $XBRA.C) 

 


Point Roberts WA, Delta BC, October 22, 2021 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining and CannabisToday’s stocks have been added to our lists of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2021/main/10221Stocks.asp

 

The newest biotech companies are all recent Nasdaq IPOs focusing on cancer therapies, kidney disease, Alzheimer’s, diseases of the skin and infectious diseases.

 

The latest mining companies are all CSE-listed with operations in North America.

 

The newest cannabis company is an international cannabis company that includes infused beverages.

 

New Stocks added to Biotech Stocks Directory:

Erasca, Inc. (NasdaqGS:ERAS) At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

 

TScan Therapeutics, Inc. (Nasdaq:TCRX) is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

 

HCW Biologics Inc. (Nasdaq: HCWB) is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation. The Company is developing novel immunotherapies designed to improve health by disrupting the link between chronic, low-grade inflammation and age-related diseases such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases and autoimmune diseases. HCW uses its TOBI™ discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties for the treatment of inflammaging. Two of HCW Biologics lead inventions via TOBI™ include molecules HCW9218 and HCW9302, both currently undergoing IND-enabling studies.

 

Imago BioSciences, Inc. (Nasdaq: IMGO) is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF.

 

Unicycive Therapeutics, Inc. (Nasdaq: UNCY) is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

 

Transcode Therapeutics, Inc. (Nasdaq: RNAZ) is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.

 

Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational immunotherapy drug, ACU193, a humanized monoclonal antibody that selectively targets toxic AβOs in a Phase I clinical trial involving early Alzheimer’s disease patients.

 

Dermata Therapeutics, Inc. (Nasdaq:DRMA) is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is currently under clinical development for the treatment of acne, psoriasis, and rosacea. Our second product candidate, DMT410, uses our Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California.

 

Eliem Therapeutics, Inc. (Nasdaq: ELYM) is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

 

Adagio Therapeutics, Inc. (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.

 

ABVC BIOPHARMA, INC. (Nasdaq: ABVC) is a clinical-stage biopharmaceutical company focused on development of therapeutic solutions in oncology/hematology, the central nervous system (CNS), ophthalmology, and medical devices related to these fields. Its current pipeline features six drugs and a medical device, ABV-1701/Vitargus®. For its drug products, it is focused on conducting proof-of-concept trials through Phase II of clinical development at world-famous research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct clinical trials through Phase III at various locations throughout the world.

 

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra's lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.

 

DICE Therapeutics, Inc. (Nasdaq: DICE) is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

 

New stocks added to Mining Stocks Directory:

Brascan Gold Inc. (CSE: BRAS) is a gold exploration issuer based in Vancouver, BC. The Company holds an option over the Vulcan Property, located in the Fort Steele Mining Division in southeastern BC.

 

Gelum Resources Ltd. (CSE: GMR) is a company focused on mineral exploration in British Columbia. Its principal project is the Eldorado Gold Property located in the Bralorne-Bridge River Gold district in south-central British Columbia.

 

Athena Gold Corporation (CSE: ATHA) is engaged in the business of mineral exploration and the acquisition of mineral property assets. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Excelsior Springs Project, located in Esmeralda County, Nevada, approximately 45 miles southwest of Goldfield, Nevada.

 

New Stocks added to Cannabis Stocks Directory:

Xebra Brands Ltd. (CSE: XBRA) is an international cannabis cultivation and product company with global brands and intellectual property. Xebra’s products range from wellness to leisure, and include beverages.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors.  Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast ,  Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and  the AI Eye Podcast.

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto CornerPlay by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate ChangeExploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 


 


 

 

 

 

 

 

 

 

 

 

 

 

Psychedelic Stock Investor News - Psyched Wellness (CSE: PSYC) Announces Successful Pilot Run, Final Flavour Profile for Calm and Shipping Pre-Orders in October

Psychedelic Stock Investor News - Psyched Wellness (CSE: PSYC) Announces Successful Pilot Run, Final Flavour Profile for Calm and Shipping P...